Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTH225
- Development stage
- Preclinical
- Lead developer
- Connecta Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CTH225 is a preclinical-stage small molecule drug candidate being developed by Connecta Therapeutics for the treatment of central nervous system (CNS) and neurodevelopmental disorders. It belongs to a chemical series of p21-activated kinase (PAK) modulators designed to regulate neuroplasticity. PAK proteins are essential for the structural and functional integrity of dendritic spines and the actin cytoskeleton; their dysregulation is implicated in various cognitive and developmental conditions. CTH225 is part of a broader pipeline following the company's lead asset, CTH120, which is currently being evaluated for Fragile X Syndrome.
02
Targets
PAK (p21-activated kinase family)
Beyond the preview
Go deeper on CTH225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTH225.